Sector pending / Pharmaceutical PreparationsUpdated 2026-05-10 22:07 UTC

FRA/DPM stock hub

FRA/DPM has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/DPMis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

3.9B

Frankfurt Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

FRA/DPM

In the news

Latest news · FRA/DPM

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E6.6

P25 n/aP50 n/aP75 n/a

ROE48.4

P25 n/aP50 n/aP75 n/a

ROIC22.1

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/DPM market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

203

Groups with data

Currency

JPY

Showing 203 of 203 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Japan
Country code	DE
Employees	3,832
Employees Change	-1,148%
Employees Change Percent	-23.05
Enterprise value	EUR 5B
Exchange	Frankfurt Stock Exchange
Financial currency	JPY
First seen	2026-05-10
Industry	Pharmaceutical Preparations
Last refreshed	2026-05-10
Market cap	EUR 3.9B
Price	EUR 8.64
Price currency	EUR
Rev Per Employee	642,724.8x
Sic	2834
Symbol	fra/DPM
Website	https://www.sumitomo-pharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	15.24%
EV Earnings	8.39x
EV/EBIT	8.51x
EV/EBITDA	7.1x
EV/FCF	19.62x
EV/Sales	2.04x
FCF yield	6.52%
P/B ratio	2.5x
P/E ratio	6.56x
P/S ratio	1.59x
PE Ratio10 Y	17.24x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	23.91%
EBITDA Margin	28.67%
FCF margin	10.39%
Gross margin	59.24%
Gross Profit	EUR 1.5B
Gross Profit Growth	19.08%
Gross Profit Growth Q	-8.18%
Gross Profit Growth3 Y	-13.09%
Gross Profit Growth5 Y	-6.67%
Net Income	EUR 598M
Net Income Growth Q	-83.5%
Net Income Growth5 Y	10.43%
Pretax Margin	20.98%
Profit Margin	24.28%
Profit Per Employee	EUR 156,064
ROA	8.12
Roa5y	-4.34
ROCE	17.95
ROE	48.39
Roe5y	-20.68
ROIC	22.11
Roic5y	-13.96

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-1.24%
Cagr15y	2.94%
Cagr1y	58.58%
Cagr3y	16.96%
Cagr5y	-8.83%
Div CAGR10	-0.9%
Div CAGR3	-14.13%
Div CAGR5	-6.87%
EPS Growth Q	-83.5
EPS Growth5 Y	10.43
FCF Growth3 Y	-12.65%
FCF Growth5 Y	-15.84%
OCF Growth Q	2,481.79%
OCF Growth3 Y	-12.2%
OCF Growth5 Y	-14.59%
Revenue Growth	21.65x
Revenue Growth Q	7.28x
Revenue Growth3 Y	-8.31x
Revenue Growth5 Y	-2.72x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.54
Assets	EUR 4.4B
Cash	EUR 311.4M
Current Assets	EUR 1.6B
Current Liabilities	EUR 1.1B
Debt	EUR 1.4B
Debt EBITDA	EUR 1.99
Debt Equity	EUR 0.9
Debt FCF	EUR 5.5
Equity	EUR 1.6B
Interest Coverage	3.59
Liabilities	EUR 2.9B
Long Term Assets	EUR 2.8B
Long Term Liabilities	EUR 1.7B
Net Cash	EUR -1.1B
Net Cash By Market Cap	EUR -27.9
Net Debt EBITDA	EUR 1.55
Net Debt Equity	EUR 0.7
Net Debt FCF	EUR 4.28
Tangible Book Value	EUR -441.3M
Tangible Book Value Per Share	EUR -1.11

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.4
Inventory Turnover	1.95
Net Working Capital	EUR 145.7M
Quick ratio	0.91
Working Capital	EUR 457M
Working Capital Turnover	EUR -0.06

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend per share	EUR 0
Last Dividend	EUR 0.05
Payout Ratio	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-11.73%
1Y total return	58.53%
200-day SMA	11.06
3Y total return	60%
50-day SMA	10.64
50-day SMA vs 200-day SMA	50under200
5Y total return	-37.02%
All Time High	32.19
All Time High Change	-73.16%
All Time High Date	2018-12-05
All Time Low	1.64
All Time Low Change	426.83%
All Time Low Date	2024-05-29
ATR	0.34
Ch YTD	-30.88
High	8.64
High52	18.8
High52 Date	2026-02-19
High52ch	-54.04%
Low	8.64
Low52	4.62
Low52 Date	2025-05-30
Low52ch	87.01%
Ma50ch	-18.79%
Price vs 200-day SMA	-21.86%
RSI	31.69
RSI Monthly	52
RSI Weekly	41.35
Sharpe ratio	0.86x
Sortino ratio	1.37
Tr YTD	-30.88
Tr15y	54.53%
Tr1m	-20.1%
Tr1w	-7.08%
Tr3m	-28%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 588.8M
Operating Income Growth Q	-39.28
Operating Income Growth5 Y	4.02
Operating margin	23.91

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	234,600,573%
Net Borrowing	-606,668,984.3
Shares Insiders	0.03%
Shares Institutions	14.07%
Shares Qo Q	0%
Shares Yo Y	0%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 255.8M
Average Volume	151.4x
Bv Per Share	3.95
CAPEX	EUR -33.6M
Ch10y	-21.3
Ch15y	27.58
Ch1m	-20.1
Ch1w	-7.08
Ch1y	58.53
Ch3m	-28
Ch3y	60
Ch5y	-39.58
Ch6m	-27.39
Change	-2.35%
Change From Open	0.01
Close	8.85
Days Gap	-2.36
Depreciation Amortization	116,944,194.8
Dollar Volume	190.1
Earnings Date	2026-05-13
EBIT	EUR 588.8M
EBITDA	EUR 706.2M
EPS	EUR 1.51
F Score	5
FCF	EUR 255.8M
FCF EV Yield	5.1x
Financing CF	-609,495,579
Fiscal Year End	March
Founded	1,897
Goodwill	1,118,504,161.5
Graham Number	10.11578
Graham Upside	17.08
Income Tax	EUR -81.3M
Investing CF	144,952,184
Is Primary Listing	0
Last Earnings Date	2026-01-30
Last Report Date	2025-12-31
Lynch Fair Value	EUR 13.73
Lynch Upside	58.95
Ma150	11.91
Ma150ch	-27.46%
Ma20	10.26
Ma20ch	-15.81%
Net CF	-224,033,803
Next Earnings Date	2026-05-13
Open	8.64
P FCF Ratio	15.34
P OCF Ratio	13.56
Position In Range	100
Ppne	241,401,050.1
Price Date	2026-05-08
Price EBITDA	EUR 5.56
Relative Volume	0.15x
Revenue	2,462,921,438x
Tax By Revenue	-3.3x
Tr6m	-27.39%
Volume	22
Z Score	1.96

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/DPM pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/DPM stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/DPM?

Insider, institutional, and short-interest positioning.

Institutional ownership

+14.1%

Share of float held by funds and institutions

Insider ownership

+0.0%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

0.0%

Negative means the company is buying back shares.

Technical

FRA/DPM momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

31.7

Neutral momentum band

Price vs 200-day MA

-21.9%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.86

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/DPM

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/DPM stock rating?

fra/DPM is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/DPM analysis?

The full report lives at /stocks/fra/DPM/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/DPM?

The latest report frames fra/DPM around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/DPM page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.